biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by LOOPA441on May 01, 2022 3:39pm

259 Views

Post# 34646188

From the Zacks report

From the Zacks report:

"While transportation, COVID and material availability related issues have delayed work, we anticipate a slowdown to the company’s timeline and one dependent on partner capacity"

I don't recall if this was in the previous report and just left in there?

Or is this new and we can expect additonal delays?

Any insight on timelines as they relate to data (007/009) and IND fillings (007/003) ?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario